TrkB-IN-1 (oral gavage; 7.25 mg/kg, 21.8 mg/kg, 43.6 mg/kg; 3 month) activates TrkB signaling cascade in the hippocampus of 5XFAD mice in a dose-dependent manner in 5XFAD mice, the ratio of p-TrkB/TrkB, p-Akt/Akt and p-ERK/ERK is also increased[1].
TrkB-IN-1 (oral gavage; 7.25 mg/kg, 21.8 mg/kg, 43.6 mg/kg; 5 days) alleviates Aβ deposition and rescues memory deficits in 5XFAD mice[1].
TrkB-IN-1 (oral gavage; 36 mg/kg) exhibits ~10.5% oral bioavailability with a Cmax?of 129 ng/mL, Tmax?of 0.5 h, and T1/2?for oral administration of 3.66 h[1].